Freshness note: This analysis was last updated 29 days ago. Fast-moving policy claims can change quickly, so check for newer official updates before relying on this verdict.
“Trump reversed all the cost caps Biden negotiated for anyone on Medicare or Medicaid”
Summary
Trump signed an executive order in January 2025 that paused certain Biden-era drug pricing initiatives, but the major Medicare drug price negotiation program and prescription cost caps remained in effect. The order targeted voluntary drug discount programs and regulatory processes, not the statutory cost caps established under the Inflation Reduction Act.
Primary Sources
FactCheck.org rated the claim as false, finding that Trump's executive order did not reverse the Medicare drug price negotiation program or prescription cost caps established by law
USA Today confirmed that Medicare drug price caps remain in place and that the executive order did not affect statutory provisions from the Inflation Reduction Act
Snopes rated the claim as mostly true regarding some rollback of drug pricing efforts, but acknowledged that major statutory provisions remained intact
Evidence Supporting the Claim
- Trump signed an executive order in January 2025 that paused or rescinded certain Biden administration drug pricing initiatives
- The executive order targeted voluntary discount programs like the 340B Drug Pricing Program and certain regulatory guidance documents
Evidence Against / Context
- The Medicare drug price negotiation program established by the Inflation Reduction Act remained in effect after Trump's executive order
- The $35 monthly insulin cap for Medicare beneficiaries, established by statute under the Inflation Reduction Act, was not affected by the executive order
- The $2,000 annual out-of-pocket cap on prescription drugs for Medicare Part D enrollees, which took effect in 2025, remained in place
- Executive orders cannot overturn provisions established by congressional legislation without new legislation
- FactCheck.org and USA Today both rated versions of this claim as false, noting that major cost caps remained intact
- Trump's executive order primarily affected regulatory guidance and voluntary programs rather than statutory cost protections
Timeline
President Biden signed the Inflation Reduction Act, establishing Medicare drug price negotiations and prescription cost caps
Multiple fact-checking organizations reviewed claims about the executive order's impact on Medicare and Medicaid cost caps
President Trump signed an executive order addressing certain drug pricing policies from the previous administration
What This Means
Structured interpretation — not opinion
Key takeaway 1
Trump's executive order affected some drug pricing initiatives but could not reverse provisions established by federal law without congressional action
Key takeaway 2
The major cost protections for Medicare beneficiaries, including the insulin cap and out-of-pocket spending limit, are statutory requirements that remain in effect
Key takeaway 3
The claim overstates the scope and impact of the executive order by asserting all cost caps were reversed when the primary legislative provisions remained unchanged
Key takeaway 4
Voluntary programs and regulatory guidance can be modified through executive action, but congressionally enacted benefit structures require legislative changes
Related Claims in health
“The FDA was changing leucovorin's label because it could help 'hundreds of thousands' of children with autism”
FDA Commissioner Marty Makary announced in September 2025 that the agency would change leucovorin's label to reflect potential benefits for some children with autism and cerebral folate deficiency. However, the FDA later clarified the label change applied to a rare subset of patients with a specific metabolic condition, not hundreds of thousands of children, and the agency disputed characterizations that overstated the scope of the change.
“The Trump administration enacted a 6-month moratorium on Minnesota Medicaid payments”
On February 27, 2026, the Trump administration implemented a six-month moratorium on federal Medicaid payments to Minnesota through the Centers for Medicare and Medicaid Services. The action was taken in response to Minnesota's policies regarding undocumented immigrants' access to state healthcare programs, which federal officials characterized as violations of federal law.
“90% of health care spending treats chronic disease”
The claim that 90% of healthcare spending treats chronic disease is an overstatement of the actual figures. Federal health agencies report that chronic diseases account for approximately 75-90% of healthcare spending, with the most commonly cited figure from the Centers for Disease Control and Prevention being 90% of the nation's $4.5 trillion in annual healthcare expenditures, though this appears to include broadly defined chronic conditions and may represent an upper-bound estimate.